Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib Meeting Abstract
| Authors: | Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; Ulaner, G. A.; Reddy, R.; Abdel-Wahab, O.; Durham, B. H. |
| Abstract Title: | Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib |
| Meeting Title: | 38th Annual Meeting of the Histiocyte Society |
| Journal Title: | Pediatric Blood and Cancer |
| Volume: | 70 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Sep 18-20 |
| Meeting Location: | Stockholm, Sweden |
| ISSN: | 1545-5009 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2023-02-01 |
| Start Page: | S10 |
| Language: | English |
| ACCESSION: | WOS:000904088900021 |
| PROVIDER: | wos |
| DOI: | 10.1002/pbc.30097 |
| Notes: | Meeting Abstract -- Meeting also held virtually -- Electronic article number: e30097 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work